Anti-CD123 antibody [IHC123] (STJA0042103)
SPECIFICATIONS
ClonalityMonoclonal
HostMouse
ConjugationUnconjugated
General Information
| Short Description | Mouse monoclonal anti-CD123 for use in IHC-p in Human samples. Datasheet included with dilution recommendations, and related reagents. |
| Applications | IHC-p |
| Host | Mouse |
| Reactivity | Human |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Clonality | Monoclonal |
| Clone ID | IHC123 |
| Conjugation | Unconjugated |
| Formulation | Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide |
| Storage Instruction | Store at 2-8°C for up to 1 year. Do not freeze. |
Target Information
| Specificity | Tested and validated on blastic plasmacytoid, dendritic cell neoplasm tissue. |
Additional Info
| Background | Cluster of Differentiation 123 (CD123) , also known as Interleukin-3 Receptor, plays an important role in regulating the immune system by transmitting interleukin-3 signals, thereby promoting proliferation and differentiation of hematopoietic stem cells. Studies suggest that the expression of CD123 is observed in most Acute Myeloid Leukemia (AML) subtypes, including leukemic stem cells. CD123 positive AML has demonstrated higher marrow blast percentages and monocytic differentiation, and clinical presentations for AML mostly include bone marrow involvement and regional lymphadenopathy. As there are overlapping clinical presentations between AML and blastic NK-cell lymphomas, differential diagnosis is important; use of a panel of CD123, CD4, CD56, and TCL-1 can help with this distinguishment between AML and myeloid involvement from blastic NK-cell lymphomas. |
Information sourced from Uniprot.org